Part D Extra Help Loss in 2026: How Losing Medicaid Disability Coverage Turns a $47 Eliquis Copay Into a $2,000 Bill
You get a letter in the mail. It says your state has redetermined your Medicaid eligibility, and because you're now considered able to work, your disability-based Medicaid coverage is ending in 60 days. If you're one of the roughly 12 million people who qualify for Medicare through age or disability and also carry Medicaid, that letter doesn't just cost you Medicaid benefits — it very likely costs you your automatic Extra Help (the Part D Low-Income Subsidy), and that's where the real financial cliff shows up.
KFF Health News recently profiled a cancer survivor caught in exactly this situation — a state work-requirement review questioning whether she was "sick enough" to keep disability-linked Medicaid, even mid-treatment. That story is a Medicaid problem on its face. But if you're a dual-eligible Medicare beneficiary, the downstream Part D consequence is the part almost nobody explains to you before it happens: you don't glide from full-subsidy pricing to standard pricing. You fall off a cliff, on a specific drug, on a specific refill date.
The decision moment: three things to check before your next Medicaid renewal
If you're a dual eligible — Medicare plus any level of Medicaid — here's what actually needs to happen, and by when:
- Check your Medicaid redetermination date now. Most states run annual reviews; work-requirement rules are tightening the screening in several states this year. A lapse in Medicaid doesn't just risk your Medicaid — it triggers a Part D subsidy redetermination.
- If Medicaid ends, apply for Extra Help directly through the Social Security Administration within 60 days. You are not automatically re-enrolled. Full or partial subsidy depends on income and resource limits that are separate from — and often stricter than — your state's Medicaid disability test.
- Check your specific drugs against your plan's formulary the moment your subsidy status changes. A Special Enrollment Period exists for loss of Extra Help, but it doesn't retroactively cover the drug costs you already paid at standard pricing while you sorted out the paperwork.
Miss any of these, and you're paying standard Part D cost-sharing on your very next fill — no phase-in period.
What Extra Help actually buys you, in dollars
Full Extra Help (LIS) eliminates the Part D deductible entirely and caps your per-prescription copay instead of exposing you to coinsurance. Losing it drops you into the standard 2026 Part D benefit structure: a $590 deductible, then 25% coinsurance until you hit the $2,000 out-of-pocket cap, then $0 for the rest of the year under the Inflation Reduction Act's catastrophic-phase redesign.
Here's what that looks like side by side for the same drug:
| Cost-sharing structure | Deductible | Coverage until $2,000 cap | What you pay per fill |
|---|---|---|---|
| Full Extra Help (LIS) | $0 | Flat copay, no coinsurance | ~$4.90 generic / ~$12.15 brand |
| Standard Part D, no subsidy | $590 (100% patient-paid) | 25% coinsurance | Full drug cost until cap is met |
That structural difference — flat copay vs. percentage coinsurance on a $590 deductible — is what makes the transition brutal for anyone on an expensive brand drug.
The worked example: Eliquis, before and after
Take a common regimen for a stroke-risk patient: Eliquis (apixaban), a brand-name blood thinner with no generic substitute for most patients until recent limited generic entry, still commonly dispensed as brand at a list price of roughly $550–$600 for a 30-day supply.
With full Extra Help: copay is capped at the LIS brand rate, roughly $12.15 per fill. Annual cost for 12 fills: $146.
Without Extra Help, standard Part D benefit: the first fill blows through the $590 deductible entirely (100% patient-paid, since a single month's supply costs more than the deductible). The remaining Eliquis cost that same month puts you into the 25% coinsurance phase. Do the math on true out-of-pocket accumulation toward the $2,000 cap: $590 (deductible) + 25% coinsurance on the next roughly $5,640 of drug cost = $1,410, which brings total true out-of-pocket to $2,000 — the annual cap — typically within the first one to two fills of a $550+/month drug. After that, $0 for the rest of the year under the IRA cap.
So the annual swing isn't gradual. It's $146 with Extra Help versus $2,000 without it — and nearly all of that $2,000 lands in month one or two, not spread evenly across the year. That's the "$47 copay to $2,000 overnight" reality: many plans place Eliquis at a roughly $45–$47 tier-3 copay for LIS partial-subsidy enrollees, and even that modest number disappears once the subsidy lapses and coinsurance takes over.
This is the kind of phase-by-phase math Toravine runs against your actual formulary and refill history — so instead of estimating from a generic example, you can see what your own drug list does to your out-of-pocket total across the deductible, coinsurance, and cap phases. If Extra Help status is at all uncertain for you this year, run your specific regimen through the Part D Extra Help income limits and $2,000 cap breakdown before your next fill, not after.
The pharmacy network wrinkle most people never see coming
There's a second, less visible way your copay can move even if your subsidy status doesn't change at all: your pharmacy's standing in the PBM's network.
Arkansas pharmacies recently filed a first-of-its-kind lawsuit against Express Scripts, using a state law that lets pharmacies sue pharmacy benefit managers for reimbursing them below NADAC — the National Average Drug Acquisition Cost. The pharmacies' argument is straightforward: if a PBM pays a pharmacy less than the drug costs to acquire, the pharmacy either eats the loss or drops out of the network. Independent and rural pharmacies are the ones most likely to close or exit a preferred network under that pressure.
Why does this matter for your Eliquis or any other maintenance drug? Because Part D plans routinely set a lower "preferred" cost-share at specific in-network pharmacies and a higher "standard" cost-share everywhere else in the same network. If your regular pharmacy drops out of preferred status — or closes — your copay on the exact same drug, same plan, same formulary tier, goes up simply because of where you fill it. Toravine's Part D pharmacy-steering analysis found this exact mechanism adding real dollars to beneficiaries' bills even when nothing about their formulary changed; you can see how PBM pharmacy steering changes your effective copay before assuming your current pharmacy will still be preferred next year.
This is also why discount coupon programs don't rescue you here: even a lower cash price at a non-preferred pharmacy doesn't count toward your deductible or your $2,000 cap the way a covered Part D claim does — a distinction we broke down in the TrumpRx coupon versus Part D deductible math.
Why CMS oversight is tightening — and why that doesn't help you this year
Two other developments point at the same underlying pattern: federal regulators are increasingly worried about intermediaries — PBMs, equipment suppliers, plan sponsors — capturing money that's supposed to reach patients or providers. The HHS Office of Inspector General recently urged CMS to crack down on durable medical equipment suppliers billing Medicare Advantage plans, saying neither CMS nor MA organizations are screening those suppliers adequately. Separately, CMS is expanding its ACCESS model in 2027 to cover more chronic conditions, using technology-based screening to catch care gaps earlier.
Both signal the same direction of travel: more scrutiny on the supply chain that sits between your premium dollars and your actual prescription bill. But oversight investigations and new demonstration models take years to change pricing on the ground. None of it changes what happens to you on your next refill if your Extra Help lapses or your pharmacy exits its preferred network this month.
The checklist to actually run before your next enrollment window
- Confirm your Medicaid/Extra Help status directly with SSA, not just your state Medicaid office — the two systems don't always update on the same timeline.
- Re-verify every drug on your regimen against next year's formulary tier, not just this year's, since tier placement resets annually and a drug that was tier 2 this year can move to tier 3 or require prior authorization next year.
- Confirm your regular pharmacy's preferred-network status for the coming plan year — don't assume it carries over, especially if it's an independent or rural pharmacy in a state involved in PBM reimbursement disputes.
- Model your true annual cost across all three Part D phases — deductible, initial coverage, catastrophic cap — for your actual drug list, because as the Eliquis example shows, losing a subsidy or a preferred pharmacy rarely changes your cost by a small percentage. It usually changes it by a phase.
If you're a dual eligible, or if you're watching a Medicaid disability redetermination land in your mailbox this year, this is exactly the kind of scenario worth modeling before it happens rather than after the bill arrives. You can run your own plan, drug list, and pharmacy network through Toravine and see the actual dollar swing — not a generic estimate — before your next enrollment deadline forces the decision for you.
Data behind this post
The figures above are computed from the product's own reference tables, last refreshed 2026-09-13:
- 6,287 rows from census_acs_medicare
- 174 rows from cms_medicare_irmaa
- 1,236 rows from cms_medicare_plan_premiums
- 3,570 rows from medigap_rates
Sources
- A Cancer Survivor Hoped To Work — Then She Lost Her Medicaid Disability Coverage — KFF Medicare
- OIG urges crackdown on equipment suppliers in Medicare Advantage — Healthcare Dive
- Express Scripts targeted by Arkansas pharmacies in first-of-its-kind lawsuit — Healthcare Dive
- 70% of Gen Z healthcare workers say they’re going to quit within the next year — Healthcare Dive
- CMS to add more chronic conditions to ACCESS model in 2027 — Healthcare Dive